{"id":"8adfd502f2a7","type":"article","url":"https://hartvaat.nl/2026/01/07/klinische-proteomics-in-de-cardiovasculaire-geneeskunde-huidige-stand-en-toekoms/","title":"Klinische proteomics in de cardiovasculaire geneeskunde: huidige stand en toekomst","title_en":"Clinical proteomics in cardiovascular medicine: Current capabilities, limitations, and future directions","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","cardiovasculaire-genetica","familiaire-hypercholesterolemie-screening","gepersonaliseerde-geneeskunde","laminopathie","menopauze","microbioom","ouderen","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00003-1/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00003-1/fulltext","authors":["Bhawana Singh","Oleg A. Karpov","Manuel Mayr"],"significance":5,"published":"2026-01-07","source_date":"2026-01-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This review discusses the current capabilities and limitations of commercial high-throughput proteomics platforms such as Olink and SomaLogic for cardiovascular research. While widely applied in biobank studies, data quality issues remain underappreciated and must be addressed for clinical translation.","created":"2026-07-03T10:25:35Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Commerciële high-throughput proteomicsplatforms zoals Olink en SomaLogic maken grootschalige epidemiologische studies mogelijk. Dit overzicht bespreekt de huidige mogelijkheden, beperkingen en toekomstige richtingen van klinische proteomics in de cardiovasculaire geneeskunde.","abstract_original":"Commercial high-throughput proteomics platforms, such as Olink and SomaLogic, enable large-scale epidemiological studies with integrated multi-omics measurements. While these proteomics approaches have been widely applied in biobanks, issues of data quality remain underappreciated. In this review, we discuss these limitations and outline a way forward for realizing the clinical translation of proteomics as a comprehensive ‘liquid health check’."}